Here are the 424B prospectus supplements from Organogenesis Holdings Inc. (ORGO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ORGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORGO filings page.
Organogenesis Holdings Inc. is establishing an at-the-market offering program to sell up to $75,000,000 of Class A common stock through BTIG and Citizens JMP as sales agents. The shares may be sold from time to time on Nasdaq or other permitted markets, with commissions of up to 3.0% of gross proceeds.
As of June 30, 2026, 128,674,548 Class A shares were outstanding and net tangible book value was $256.4 million, or $1.99 per share. If 31,645,569 shares were sold at $2.37 for $75 million in gross proceeds, as-adjusted net tangible book value would rise to $2.05 per share, implying $0.32 per-share dilution to new investors.
The company intends to use net proceeds with existing cash for working capital and general corporate purposes, including facility expansion, manufacturing enhancements, salesforce expansion, clinical studies, regulatory approvals and additional commercial insurance coverage. Organogenesis also highlights its BLA for ReNu for knee osteoarthritis pain, accepted by the FDA with a PDUFA target action date of April 24, 2027.